

Ref: FOIA Reference 2021/22-371

Date: 22nd November 2021

Email foi@uhnm.nhs.uk

Dear

I am writing to acknowledge receipt of your email dated 19th October 2021 requesting information under the Freedom of Information Act (2000) regarding head and neck cancer.

On 20th October 2021 we contacted you via email to inform you that UHNM was aggregating this request with your request on Neurology drugs (previous reference 321-2122)

Your new reference number for **both** requests is 371-2122

The section 12 exemption states:

The authority can combine related requests received within a period of 60 consecutive days from:

- The same person or
- People who appear to be acting in concert or in pursuance of a campaign.

On 3rd November you sent in other request for Neurology drugs- this is identical to your previous request (321-2122) and therefore we responded by informing you that we would be aggregating this with the other two and that the reference for all three requests would be 371-2111

As of 1st November 2014 University Hospitals of North Midlands NHS Trust (UHNM) manages two hospital sites – Royal Stoke University Hospital, and County Hospital (Stafford). Therefore the response below is for the two sites combined from that date where appropriate.

Request # 1

Q1 I am analysing the treatment of neurology patients within secondary care. Could you please answer the following four questions?

1. How many patients have been treated with the following drugs (for any disease) in the past 6 months?

- **Aubagio (teriflunomide)**
- **Avonex (interferon beta-1a)**
- **Betaferon (interferon beta-1b)**
- **Brabio (glatiramer acetate)**

- **Copaxone (glatiramer acetate)**
- **Extavia (beta interferon-1b)**
- **Fampyra (fampridine)**
- **Gilenya (fingolimod)**
- **Lemtrada (alemtuzumab)**
- **Mavenclad (cladribine)**
- **Mayzent (siponimod)**
- **Ocrevus (ocrelizumab)**
- **Plegridy (peginterferon beta-1a)**
- **Rebif (beta interferon-1a)**
- **Tecfidera (dimethyl fumarate)**
- **Tysabri (natalizumab)**
- **Zeposia (ozanimod)**

A1 We are unable to provide the information you require in the requested format as to release this data could lead to the identification of the person(s) involved due to the low numbers involved, and would breach the Trusts obligations under Data Protection Act 2018. Accordingly, this aspect of your request is exempt from disclosure under the terms of Section 40(2) of the FOI Act. *Personal information*. However as the Trust is committed to openness and transparency we can band the numbers as being <5

This exemption is an absolute exemption and therefore no consideration of the public interest test is needed. See below:

- Aubagio (teriflunomide) = 15
- Avonex (interferon beta-1a) = 18
- Betaferon (interferon beta-1b) = <5
- Brabio (glatiramer acetate) = 0
- Copaxone (glatiramer acetate) = 60
- Extavia (beta interferon-1b) = 0
- Fampyra (fampridine) = 0
- Gilenya (fingolimod) = 64
- Lemtrada (alemtuzumab) = <5
- Mavenclad (cladribine) = 0
- Mayzent (siponimod) = 0
- Ocrevus (ocrelizumab) = 234
- Plegridy (peginterferon beta-1a) = 22
- Rebif (beta interferon-1a) = 30
- Tecfidera (dimethyl fumarate) = 167
- Tysabri (natalizumab) = 236
- Zeposia (ozanimod) = 0

Q2 How many patients have been treated with the following drugs in the past 4 months:

- **Aimovig (erenumab) - any disease**
- **Ajovy (fremanezumab) - any disease**
- **Emgality (galcanezumab) - any disease**
- **Botulinum Toxin (i.e. Botox, Dysport, Xeomin) – for migraine ONLY**

A2 See below:

- Aimovig (erenumab) - any disease = zero
- Ajovy (fremanezumab) - any disease = 74
- Emgality (galcanezumab) - any disease = zero

- Botulinum Toxin (i.e. Botox, Dysport, Xeomin) – for migraine ONLY = 191

Q3 Does the Trust either commission or fund Botulinum Toxin treatment and/or anti-CGRP monoclonal antibody treatments (Ajovy, Aimovig, Emgality) for migraine (Y/N)?

A3 Commissioned by NHSE/CCGs

Q4 How many patients have been treated in the past 4 months for the following conditions?

- Chronic migraine (15+ headache days per month)
- Episodic migraine (4-14 headache days per month)
- Relapsing remitting multiple sclerosis (RRMS)
- Primary progressive multiple sclerosis (PPMS)
- Secondary progressive multiple sclerosis (SPMS)

A4 I can confirm that the Trust holds information regarding this question but feel this information is exempt under section 21: *information reasonably accessible by other means*. This is because the information is available via the Trust's public website at the following link: as per our response to you on reference 065-2021- April 2021

<http://www.uhnm.nhs.uk/about-us/regulatory-information/freedom-of-information-publication-scheme/freedom-of-information-disclosure-log/>

Request #2

Q1 We are investigating the incidence and treatment of different types of cancer in the UK. We would greatly appreciate if you could answer the following three questions:

1. Within your health Trust, how many patients have been treated in the past 3 months for head and neck cancer (squamous cell carcinoma) with the following agents?

- Carboplatin (monotherapy or in combination with 5-FU)
- Cisplatin (monotherapy or in combination with 5-FU)
- Cetuximab with/without chemotherapy
- Cetuximab with radiotherapy
- Pembrolizumab monotherapy
- Pembrolizumab with chemotherapy
- Nivolumab
- Docetaxel (monotherapy or in combination with 5-FU)
- Fluorouracil (5FU)
- Radiotherapy only
- Other

A1 We are unable to provide the information you require in the requested format as to release this data could lead to the identification of the person(s) involved due to the low numbers involved, and would breach the Trusts obligations under Data Protection Act 2018. Accordingly, this aspect of your request is exempt from disclosure under the terms of Section 40(2) of the FOI Act. *Personal information*. However as the Trust is committed to openness and transparency we can band the numbers as being <5

This exemption is an absolute exemption and therefore no consideration of the public interest test is needed. See below:

- Carboplatin (monotherapy or in combination with 5-FU) = 8
- Cisplatin (monotherapy or in combination with 5-FU) = 15
- Cetuximab with/without chemotherapy = 0
- Cetuximab with radiotherapy = 0
- Pembrolizumab monotherapy = 6
- Pembrolizumab with chemotherapy = 0
- Nivolumab = <5
- Docetaxel (monotherapy or in combination with 5-FU) – Included in Cisplatin/Carboplatin Numbers
- Fluorouracil (5FU) = 0
- Radiotherapy only
- Other = 0

Q2 For the patients treated in the past 3 months for head and neck cancer (squamous cell carcinoma) with the therapies listed in the first question, please provide:

- **Total number of head and neck cancer patients**
- **Number of locally advanced head and neck cancer patients**
- **Number of recurrent and/or metastatic head and neck cancer patients**

A2 See below:

- Total number of head and neck cancer patients = 33
- Number of locally advanced head and neck cancer patients = 26
- Number of recurrent and/or metastatic head and neck cancer patients = 7

Q3 Within your health Trust, how many patients have been treated in the past 3 months with the following agents for colorectal cancer [CRC]?

- **Aflibercept**
- **Bevacizumab**
- **Capecitabine**
- **CAPIRI**
- **CAPOX (XELOX)**
- **Cetuximab in combination with FOLFIRI**
- **Cetuximab in combination with FOLFOX**
- **Cetuximab not in combination with FOLFIRI or FOLFOX**
- **Irinotecan only**
- **FOLFIRI**
- **FOLFOX**
- **Fluorouracil (5FU) only**
- **Oxaliplatin only**
- **Panitumumab in combination with FOLFIRI**
- **Panitumumab in combination with FOLFOX**
- **Panitumumab not in combination with FOLFIRI or FOLFOX**
- **Pembrolizumab**
- **Nivolumab**
- **Raltitrexed**
- **Ramucirumab**
- **Regorafenib**

- **Sorafenib**
- **Other SACT**

A3 We are unable to provide the information you require in the requested format as to release this data could lead to the identification of the person(s) involved due to the low numbers involved, and would breach the Trusts obligations under Data Protection Act 2018. Accordingly, this aspect of your request is exempt from disclosure under the terms of Section 40(2) of the FOI Act. *Personal information*. However as the Trust is committed to openness and transparency we can band the numbers as being <5

This exemption is an absolute exemption and therefore no consideration of the public interest test is needed. See below:

- Afibercept = 0
- Bevacizumab = 0
- Capecitabine = 5
- CAPIRI = 8
- CAPOX (XELOX) = 75
- Cetuximab in combination with FOLFIRI = 20
- Cetuximab in combination with FOLFOX = <5
- Cetuximab not in combination with FOLFIRI or FOLFOX = 0
- Irinotecan only = <5
- FOLFIRI = 33
- FOLFOX - 25
- Fluorouracil (5FU) only = <5
- Oxaliplatin only = 0
- Panitumumab in combination with FOLFIRI = <5
- Panitumumab in combination with FOLFOX = 0
- Panitumumab not in combination with FOLFIRI or FOLFOX = 0
- Pembrolizumab = <5
- Nivolumab <5
- Raltitrexed = 0
- Ramucirumab = 0
- Regorafenib = 0
- Sorafenib = 0
- Other SACT = 0

Request # 3

Q1 I would like to raise a freedom of information request to your trust around the treatment of neurology patients within secondary care, could you please help by providing the patient numbers I have requested below:

1. How many patients have been treated with the following drugs (for any disease) in the past 6 months:

- **Aubagio (teriflunomide)**
- **Avonex (interferon beta-1a)**
- **Betaferon (interferon beta-1b)**
- **Brabio (glatiramer acetate)**
- **Copaxone (glatiramer acetate)**
- **Extavia (beta interferon-1b)**

- Fampyra (fampridine)
- Gilenya (fingolimod)
- Lemtrada (alemtuzumab)
- Mavenclad (cladribine)
- Mayzent (siponimod)
- Ocrevus (ocrelizumab)
- Plegridy (peginterferon beta-1a)
- Rebif (beta interferon-1a)
- Tecfidera (dimethyl fumarate)
- Tysabri (natalizumab)
- Zeposia (ozanimod)

A1 As request #1

Q2 How many patients have been treated with the following drugs in the past 4 months:

- Aimovig (erenumab) - any disease
- Ajovy (fremanezumab) - any disease
- Emgality (galcanezumab) - any disease
- Botulinum Toxin (i.e. Botox, Dysport, Xeomin) –for migraine ONLY

A2 As request #1

Q3 Does the Trust either commission or fund Botulinum Toxin treatment and/or anti-CGRP monoclonal antibody treatments (Ajovy, Aimovig, Emgality) for migraine (Y/N)?

A3 As request #1

Q4 How many patients have been treated in the past 4 months for the following conditions:

- Chronic migraine (15+ headache days per month)
- Episodic migraine (4-14 headache days per month)
- Relapsing remitting multiple sclerosis (RRMS)
- Primary progressive multiple sclerosis (PPMS)
- Secondary progressive multiple sclerosis (SPMS)

A4 As request #1

*Please note that any individuals identified do not give consent for their personal data to be processed for the purposes of direct marketing.

UHNM NHS Trust is a public sector body and governed by EU law. FOI requestors should note that any new Trust requirements over the EU threshold will be subject to these regulations and will be advertised for open competition accordingly.

Where the Trust owns the copyright in information provided, you may re-use the information in line with the conditions set out in the Open Government Licence v3 which is available at <http://www.nationalarchives.gov.uk/doc/open-government-licence/version/3/>. Where information was created by third parties, you should contact them directly for permission to re-use the information.

An anonymised copy of this request can be found on the Trust's disclosure log, please note that all requests can be found at the following link: <http://www.uhnm.nhs.uk/aboutus/Statutory-Policies-and-Procedures/Pages/Freedom-of-Information-Disclosure-Log.aspx>

This letter confirms the completion of this request. A log of this request and a copy of this letter will be held by the Trust.

If you have any queries related to the response provided please in the first instance contact my office.


Should you have a complaint about the response or the handling of your request, please also contact my office to request a review of this. If having exhausted the Trust's FOIA complaints process you are still not satisfied, you are entitled to approach the Information Commissioner's Office (ICO) and request an assessment of the manner in which the Trust has managed your request.

The Information Commissioner may be contacted at:

Information Commissioner's Office, Wycliffe House, Water Lane, Wilmslow, Cheshire SK9 5AF or via www.ico.org.uk.

If following review of the responses I can be of any further assistance please contact my secretary on 01782 671612.

Yours,



Jean Lehnert
Data, Security & Protection Manager